Synthetic peptides have become one of the fastest growing market sectors in the pharmaceutical and biopharmaceutical industries, with greater efficacy, safety, and tolerability than many small molecule drugs. Understanding structure and impurities is key to ensuring critical quality and safety standards are met. With Waters workflow-based solutions for lab-scale purification, characterization, and monitoring of synthetic peptides and their impurities, your lab has the user-friendly tools to improve drug development and manufacture.
Combining state-of-the-art column and system technology, MaxPeak Premier Solutions are designed specifically to eliminate the unpredictability of analyte losses due to metal interactions.
Make better and faster decisions, maximize organizational efficiency, and directly measure multiple synthetic peptide quality attributes with the BioAccord LC-MS System.
Maximize sample information for your analytes from detailed characterization to accurate quantitation with the Xevo G3 QTof, which enables complete confidence in your results.
Obtain ultimate flexibility with the SYNAPT XS Mass Spectrometer that offers greater freedom of analytical choice to support scientific creativity and technical success for any application.
Monitor peptide drug product quality efficiently and minimize the risk of unexpected components cost-effectively using the ACQUITY QDa II Detector in your workflow.
Obtain simple mass detection ideally suited to qual/quan applications with the SQ Detector 2, an advanced benchtop single quadrupole mass detector designed for high performance LC-MS applications that offers a wide range of ionization options including APPI and ASAP.
Achieve flexible, scalable preparative LC configurations with the specificity of mass-directed purification or inclusiveness of UV detection with Waters Purification Systems.
UPLC is used for pilot-scale analysis because it is best able to chromatographically resolve the peak of interest, a 1500 Da synthetic peptide, from its related impurities.
Optimizing the gradient segment for peptide analysis. The synthetic peptide was separated with UPLC at a gradient slope of 3%/column volume over 8% segments beginning at 28, 30, and 33% acetonitrile. Separations were monitored with UV at 214 nm.
Optimized separation of synthetic peptide eledoisin with orthogonal mass detection. 1A) UV detection at 215 nm. Using the MassLynx integration tool, 11 impurity peaks were identified and annotated with their retention time and area. Peaks above 0.2% area are labeled in blue, otherwise in red. 1B) MS detection by ACQUITY QDa Detector.
Synthetic peptide separation of eledoisin from its process-related impurities. 1A) Optical detection of eledoisin with inset showing impurities. 1B) Corresponding QDa data. Inset shows strong visual correlation to optical data.
Representative chromatogram of method performance for both MaxPeak HPS Technology and traditional stainless-steel systems for semaglutide. MaxPeak HPS Technology provided a 20% increase in peak area and 30% increase in peak height compared to traditional stainless steel column hardware.
Example chromatograms of daptomycin and dalbavancin run on the Arc Premier featuring MaxPeak HPS Technology (trace in black) vs ACQUITY Arc Systems featuring traditional stainless steel (trace in blue). A significant increase in chromatographic peak area and height can be seen on the Arc Premier System in combination with XSelect Premier Peptide CSH C18 columns.
